Skip to main content

Table 2 Definition of poor risk localised disease and indications for busulfan and melphalan (BuMel) high-dose therapy

From: International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

Case

Localised disease

Resected at diagnosis

Volume ≥200 mL

Pre-operative RT

Histological response

≥10% viable tumour

Unresectable tumour treated with RT alone

Volume <200 mL but poor radiological response i.e., <50% regression with chemotherapy

RT contraindications to BuMela

Other medical contraindications to BuMela

BuMel recommended

1

N

n/r

n/r

n/r

n/r

n/r

n/r

n/r

n/r

N

2

Y

Y

N

n/r

n/r

n/r

n/r

n/r

n/r

N

3

Y

Y

Y

n/r

n/r

n/r

n/r

N

N

Y

4

Y

N

N

n/r

Y

n/r

n/r

N

N

Y

5

Y

N

N

Y

Y

n/r

n/r

N

N

Y

6

Y

N

Y

N

Y

n/r

n/r

N

N

Y

7

Y

N

Y

Y

Y

n/r

n/r

N

N

Y

8

Y

N

Y

Y

N

n/r

n/r

N

N

Y

9

Y

N

Y

Y

n/ab

n/r

n/r

N

N

Y

10

Y

N

Y

N

n/a

Y

n/r

N

N

Y

11

Y

N

N

N

n/a

Y

Y

N

N

Y

  1. n/a not available, n/r not relevant, RT radiotherapy
  2. aIf response is yes, then high-dose therapy is contraindicated
  3. bFor example, if extracorporeal irradiation of primary tumour is used prior to re-implantation
Back to article page

Trials

ISSN: 1745-6215